The limited clinical data in patients with breast cancer treated with trastuzumab and/or lapatinib suggest that anti-HER2 agents appear to be safe on the ovaries (Ruddy et al., 2015; Lambertini et al., 2019), and they seem to only slightly reduce ovarian reserve when administered as single agent without concurrent chemotherapy (Lambertini et al., 2023). Here, ERBB2 is linked to breast carcinoma.